

# NOVACYT

**Novacyt S.A.**  
**("Novacyt", the "Company" or the "Group")**

## **AGM Voting**

**Paris, France, and Manchester, UK – 28 May 2025** – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, will be holding its Annual General Meeting ("AGM") at 1pm CEST/12pm BST on Thursday, 19 June 2025 at the Hilton Hotel, Charles de Gaulle Airport, 8 Rue de Rome, 93290 Tremblay-en-France, France. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at [www.novacyt.com/investors](http://www.novacyt.com/investors).

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions set out below.

Shareholders can vote in advance of the AGM by:

- Downloading a copy of the proxy voting form from the website [www.novacyt.com/investors](http://www.novacyt.com/investors), completing it and returning it together with evidence of their shareholding which must be in the form of a share certificate (attestation), either by post to the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or via email to the following address: [serviceproxy@cic.fr](mailto:serviceproxy@cic.fr), or [investor.relations@novacyt.com](mailto:investor.relations@novacyt.com), no later than 15 June 2025 inclusive.
- Voting on-line using the Votaccess portal <http://www.actionnaire.cic-marketsolutions.eu> if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 28 May 2025 to 18 June 2025 at 2pm BST/3pm CEST.
- Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

Participation in the AGM is confined to shareholders who can prove that their shares are registered in their name or in the name of the intermediary registered on their behalf by the second business day prior to the AGM, **16 June 2025 at Midnight, Paris time (12am CEST/11pm BST)**:

- either in the registered securities accounts kept by the company, or
- in bearer securities accounts kept by the authorised intermediary.

Shareholders wishing to attend the AGM in person may:

- For shareholders whose shares are registered with CIC: present themselves on the day of the Annual General Meeting, with proof of identity.

- Shareholders whose shares are registered in bearer form: ask the authorised intermediary who manages their securities account to send them a proof of shareholding or a letter of representation, evidencing that they hold shares of Novacyt.

Shareholders can also request an admission card in advance (a) from CIC Services, by post to the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the following address: [serviceproxy@cic.fr](mailto:serviceproxy@cic.fr); or (b) on the secure VOTACCESS platform accessible via the website <https://www.actionnaire.cic-marketsolutions.eu>.

Shareholders who have already voted (through a proxy, via their broker, nominee, bank, authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM but will not be able to vote twice.

Following the meeting, a recording of the AGM will be available on the Company's website at [www.novacyt.com/investors](http://www.novacyt.com/investors).

## **Contacts**

### **Novacyt SA**

Lyn Rees, Chief Executive Officer  
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

**Via Walbrook PR**

### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

### **Deutsche Numis (Joint Broker)**

Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

### **Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

### **Walbrook PR (Financial PR & IR)**

Paul McManus / Lianne Applegarth  
Alice Woodings

+44 (0)20 7933 8780 or [novacyt@walbrookpr.com](mailto:novacyt@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7407 804 654

## **About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))**

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

### **Clinical**

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

### **Instrumentation**

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

**Research Use Only**    Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)